CL097

Research use only, not for human use.

CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production.

CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production.(In Vitro):CL097 (0, 0.5, 2.5, 5, and 10 μg/mL) induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils. CL097 (0.1 μM) induces activation of NF-κB in TLR7-transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells.(In Vivo):in NOD mice, CL097 (5 mg/kg, s.c.) causes a modest specific lysis of the target peptide (～25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone.

——

Immunology/Inflammation

ROS

5-LOX

——

——

1026249-18-2

242.3

C13H14N4O

>98% (HPLC)

——

CCOCC1=NC2=C(N1)C(N)=NC1=C2C=CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years